RLM.L Regulatory News (RLM)

8 Oct 2007 12:00

PuriCore (LSE:PURI), the life sciences company focused on thecontrol of infectious pathogens, today announced that the US Patentand Trademark Office has granted US Patent No. 7,276,255, entitledWound and Ulcer Treatment with Super-Oxidized Water relating to woundtherapy methods. PuriCore's methods employ hypochlorous acid atneutral or near-neutral pH to enhance the healing process for wounds.Related patents have been approved previously for PuriCore'stechnology in the UK and Europe. £ PuriCore's invention is broadly drawn to methods of treating anyopen wound with hypochlorous acid solutions at neutral or near-neutralpH including two important processes, reducing wound bioburden andpromoting tissue repair. Research data submitted with the patent showsthat PuriCore's invention method provides an optimum wound-healingenvironment by decreasing the bioburden of harmful microorganismswithin the wound and by promoting skin cell proliferation andre-growth. £ "Our research indicates that hypochlorous acid solutions representa new and effective class of treatment for hard-to-heal wounds," saidGreg Bosch, CEO of PuriCore. "The granting of this first US patentspecific for wound therapy complements our broad intellectual propertyportfolio focused on antimicrobial solutions and devices for producingthese solutions." £ About PuriCore's Wound Therapy Solution £ PuriCore's patented wound therapy technology is beingcommercialized as the Vashe(TM) Wound Therapy System, a novel,noninvasive, easy-to-use wound management process that has been shownto be complementary to existing treatment methods. The Vashe System isan FDA-cleared medical device used for moistening, irrigating,cleaning, and debriding acute and chronic wounds including stage Ithrough IV pressure ulcers, stasis ulcers, diabetic ulcers,post-surgical wounds, first and second degree burns, abrasions, andminor irritations of the skin. The Vashe Solution mimics the humanbody's own infection fighter, hypochlorous acid. Recent and ongoingclinical case studies show that the Vashe Solution eliminatespathogens that produce harmful toxins and odor and cause significantpain, without any damage to tissue. Research to date demonstrates thatthe Vashe Solution provides a safe and effective alternative tocytotoxic antimicrobial and antiseptic products currently used totreat infected wounds and surgical sites and is an important elementin the overall clinical process of effective wound management. £ About PuriCore £ PuriCore (London Stock Exchange:PURI) is a life sciences companyfocused on developing and commercializing proprietary products thatsafely, effectively, and naturally kill contagious pathogens.PuriCore's technology provides a solution to a broad range of marketsthat depend upon controlling contamination, including food safety,medical device disinfection, wound therapy, and hospitality. TheCompany's proprietary technology mimics the human body's production ofthe natural antimicrobial hypochlorous acid, which is highly effectivein killing bacteria, viruses, and fungal spores. Deployinghypochlorous acid solutions as soaks, sprays, mists, and in otherforms, PuriCore's technology is designed to limit the spread ofinfectious disease, including major public health threats of M.tuberculosis, MRSA, E.coli, norovirus, avian influenza, HIV, poliovirus, Helicobater pylori, and Legionella. PuriCore is headquarteredin Malvern, Pennsylvania, with offices in Stafford, UK. £ To receive additional information on PuriCore, please visit ourweb site at www.puricore.com, which does not form part of this pressrelease. Copyright Business Wire 2007